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SUMMARY
Variants in the gene locus encoding protein tyrosine
phosphatase non-receptor type 2 (PTPN2) are
associated with inflammatory disorders, including
inflammatory bowel diseases, rheumatoid arthritis,
and type 1 diabetes. The anti-inflammatory role of
PTPN2 is highlighted by the fact that PTPN2-defi-
cient mice die a fewweeks after birth because of sys-
temic inflammation and severe colitis. However, the
tissues, cells, and molecular mechanisms that
contribute to this phenotype remain unclear. Here,
we demonstrate that myeloid cell-specific deletion
of PTPN2 in mice (PTPN2-LysMCre) promotes intes-
tinal inflammation but protects from colitis-associ-
ated tumor formation in an IL-1b-dependent manner.
Elevated levels ofmature IL-1b production in PTPN2-
LysMCre mice are a consequence of increased in-
flammasome assembly due to elevated phosphory-
lation of the inflammasome adaptor molecule ASC.
Thus, we have identified a dual role for myeloid
PTPN2 in directly regulating inflammasome activa-
tion and IL-1b production to suppress pro-inflamma-
tory responses during colitis but promote intestinal
tumor development.
INTRODUCTION
In recent decades, inflammatory bowel disease (IBD), with its
sub-forms ulcerative colitis (UC) and Crohn’s disease (CD), has
emerged as an increasing health problem in developed coun-
tries. There is evidence that genetic as well as environmental fac-
tors contribute to disease pathophysiology, and large genome-
wide association studies have associated variants in more than
200 genetic loci with IBD (Wellcome Trust Case Control Con-
sortium, 2007; Liu et al., 2015). Two of these variants are located
within the gene encoding protein tyrosine phosphatase non-re-
ceptor type 2 (PTPN2; also known as T cell protein tyrosine
phosphatase [TC-PTP]) (Wellcome Trust Case Control Con-
sortium, 2007; Glas et al., 2012; Scharl et al., 2012), which
negatively regulates pro-inflammatory signaling cascades (Aradi
et al., 2015; Scharl et al., 2010, 2011, 2012). Of note, variants
within the PTPN2 gene are associated not only with IBD but
also with other inflammatory disorders, such as rheumatoid
arthritis and type 1 diabetes (Wellcome Trust Case Control Con-
sortium, 2007; Todd et al., 2007). Ptpn2-deficient (Ptpn2/)
mice suffer from severe systemic inflammation and die
4–5 weeks after birth because of multiple organ dysfunction as
well as severe intestinal and systemic inflammation (You-Ten
et al., 1997; Heinonen et al., 2004). However, the tissue- and
cell-specific contribution to this phenotype remains poorly un-
derstood. T cell-specific loss of PTPN2 results in increased
numbers of effector andmemory CD8+ T cells, promotes autoim-
mune syndrome, and increases susceptibility to intestinal inflam-
mation (Spalinger et al., 2015;Wiede et al., 2011). Loss of PTPN2
in intestinal epithelial cells (IECs) has profound effects on cyto-
kine secretion and barrier function in vitro (Scharl et al., 2011)
but does not significantly affect intestinal inflammation in vivo
(Kasper et al., 2016). Cell culture studies in myeloid cells demon-
strated that loss of PTPN2 enhances interferon (IFN)-g, inter-
leukin (IL)-6, and IL-1b secretion (Aradi et al., 2015; Scharl
et al., 2010, 2011, 2012). Initial studies characterizing Ptpn2/
mice identified that loss of PTPN2 impaired the bone marrow
microenvironment (You-Ten et al., 1997) and made splenic mac-
rophages more responsive to lipopolysaccharide (LPS) ex vivo
(Heinonen et al., 2004). This suggests that myeloid cell function
is disturbed in Ptpn2/ mice, but the in vivo importance of
PTPN2 function inmyeloid cells has not been addressed thus far.
In the microbe-rich environment of the intestine, resident
myeloid cells exert important immune-regulatory functions (i.e.,
removal of dead cells, elimination of invading pathogens, and
the production of the anti-inflammatory cytokines TGF-b1 and
IL-10; reviewed in Zigmond and Jung, 2013). During inflamma-
tion, blood monocyte-derived macrophages, which predomi-
nantly secrete pro-inflammatory cytokines (e.g., IL-1b, TNF,
and IL-6), accumulate in the tissue (Rivollier et al., 2012; Zigmond
and Jung, 2013).
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The inflammasome products IL-1b and IL-18 are particularly
important for initiating early immune reactions against invading
pathogens (Martinon et al., 2002). Although pro-inflammatory
in nature, the role of inflammasomes in intestinal pathologies re-
mains controversial: IL-1b and IL-18 levels are highly increased
in active lesions in IBD patients (Street et al., 2004; Li et al.,
2004), and some studies have demonstrated that mice deficient
in the inflammasome receptor NLRP3, the adaptor ASC, or IL-1b
are protected from experimental colitis and induction and pro-
gression of colorectal carcinoma (CRC) (Bauer et al., 2010; Allen
et al., 2010). However, other studies have shown the opposite,
with NLRP3-, ASC-, and caspase-1-deficient mice being highly
susceptible to colitis induction (Hirota et al., 2011; Zaki et al.,
2010).
Here, we investigated the functional importance of PTPN2
in myeloid cells in vivo with respect to modulating intestinal
inflammation and tumorigenesis. We demonstrate that PTPN2
is an important regulator of inflammasome activation, and its
loss in myeloid cells promotes intestinal inflammation but, coun-
terintuitively, protects from colitis-associated tumors in an in-
flammasome- and IL-1b-dependent manner.
RESULTS
Deletion of PTPN2 in Myeloid Cells
To address the role of PTPN2 in myeloid cells, mice with a floxed
Ptpn2 gene (Ptpn2fl/fl mice [Spalinger et al., 2015], referred to
as wild-type [WT] throughout) were crossed with mice express-
ing Cre-recombinase under the lysozyme promoter (Clausen
et al., 1999) to generate mice lacking PTPN2 in myeloid cells
(PTPN2-LysMCre mice). In contrast to CD3+ T cells, B220+
B cells, or F4/80+ macrophages from WT littermates, F4/80+
cells from PTPN2-LysMCre mice did not express PTPN2 (Fig-
ures S1A and S1B), confirming efficient deletion of Ptpn2 in
macrophages. Similar results were obtained using immunofluo-
rescent staining of intestinal samples for F4/80 and PTPN2 (Fig-
ure S1C). Next, we analyzed mononuclear cell populations in the
lamina propria, mesenteric lymph nodes, and the spleen for the
extent of Ptpn2 deletion. As expected, deletion was efficient in
macrophages and monocytes, while there was no reduction of
Ptpn2 expression among CD11c+ dendritic cells (Figures S2A
and S2B). We did observe reduced Ptpn2 expression in sorted
neutrophils (Figures S2A and S2B), which is consistent with
published reports of the LysMCre mouse (Clausen et al., 1999).
Despite the decrease of Ptpn2 in neutrophils, we continued our
studies using the LysMCre strain because other macrophage-
targeting Cre strains (i.e., the F4/80-Cre line) target only tissue-
resident but not recently recruited monocyte-derived macro-
phages (Schaller et al., 2002; Abram et al., 2014). We also found
reduced proportions of monocytes in the spleen of PTPN2-
LysMCre mice but not in mesenteric lymph nodes or the lamina
propria (Figures S2A and S2B). Furthermore, numbers of
CD103+ dendritic cells (DCs) were enhanced in mesenteric
lymph nodes but reduced in the lamina propria of PTPN2-
LysMCre mice (Figures S2A and S2B). Of note, we did not
observe differences in the development of bone marrow-derived
macrophages (BMDMs) or major histocompatibility complex
(MHC)-II induction upon treatment with LPS (Figure S2C).
Loss of PTPN2 in Myeloid Cells Aggravates Colitis
To identify the consequences of myeloid cell-specific deletion
of PTPN2 on intestinal inflammation, we induced acute colitis
in PTPN2-LysMCre mice and WT littermates by administration
of 2.5% dextran sulfate sodium (DSS) in drinking water for
7 days. Although DSS-induced body weight loss and colon
shortening did not differ significantly from WT mice (Figures 1A
and 1B), PTPN2-LysMCre mice suffered from pronounced
colitis, as observed in colonoscopy, by increased levels of mye-
loperoxidase (MPO), increased spleen weight, and increased
histology scores in the terminal colon (Figures 1C–1F). PTPN2-
LysMCre mice were also more susceptible to inflammation in
the more disease-relevant, chronic DSS colitis model. These
mice showed delayed recovery after each DSS cycle, increased
spleen weight, increased MPO, and pronounced shortening
of the colon. However, unlike in the acute DSS colitis model,
histology scores were not different in PTPN2-LysMCre mice
compared with WT mice in chronic DSS colitis (Figure S3).
Although DSS colitis does involve macrophage activation, it is
a T cell-independent chemical injury model. To assess the
role of PTPN2 in myeloid cells in an immune cell-driven colitis
model, we crossed PTPN2-LysMCre mice onto the IL-10/
background. We observed that several inflammatory parame-
ters, including incidences of rectal prolapse, endoscopy
scores, MPO levels, spleen weight, and histology scores in adult
(50 days old) and aged (150 days old) mice dramatically
increased in IL-10/ mice lacking PTPN2 in myeloid cells
(IL-10xPTPN2-LysMCre mice) compared with IL-10/ mice
(Figure 2). Overall, these data clearly indicate that PTPN2-
LysMCre mice demonstrate enhanced susceptibility to colitis
in a variety of experimental models.
Reduced Tumor Load in PTPN2-LysMCre Mice
Intestinal inflammation can trigger intestinal hyperplasia in
response to colitis, and indeed we observed increased levels
of proliferating (Ki67+) cells in DSS-treated PTPN2-LysMCre
mice (Figure 3A). Because enhanced proliferation might pro-
mote tumor formation and progression, we next investigated
if PTPN2-LysMCre mice are more prone to inflammation-
driven tumorigenesis by challenging them with the AOM/DSS
model of colorectal carcinogenesis. WT mice developed
several medium-sized to large tumors, but tumors were less
frequent and much smaller in PTPN2-LysMCre littermates (Fig-
ures 3B–3D). This indicates that myeloid cell-specific loss of
PTPN2 promotes proliferation but protects against induction
of CRC. Of interest, mice lacking PTPN2 in IEC (PTPN2-VilCre
mice; Kasper et al., 2016) also showed reduced tumor burden
compared with WT littermates (Figures 3E–3G), although this
phenotype was less pronounced than in PTPN2-LysMCre
mice.
Altered Cytokine Profile in the Inflamed Intestine upon
Myeloid Cell-Specific Deletion of PTPN2
To understand the mechanism by which loss of PTPN2
in myeloid cells exacerbates colitis but restricts inflamma-
tion-driven CRC formation, we measured the expression of
pro- and anti-inflammatory cytokines in colon tissue. PTPN2-
LysMCre mice expressed enhanced mRNA levels of the
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Figure 1. Loss of PTPN2 in Myeloid Cells Promotes Acute Intestinal Inflammation
Acute colitis was induced in WT and PTPN2-LysMCre mice.
(A–G) Shown are weight change (A), colon length (B), representative pictures from colonoscopy (C) and respective statistical analysis (D), myeloperoxidase (MPO)
activity (E), spleen weight (F), and representative pictures and scoring of epithelial damage and inflammatory infiltration in the terminal colon (G).
Depicted are pooled results from two independent experiments with four to six mice per group. Asterisks denote significant differences (*p < 0.05, **p < 0.01,
and ***p < 0.001; Mann-Whitney U test with Bonferroni correction). Scale bars represent 100 mm. Error bars represent means ± SD. See Figures S1–S3 for
characterization of PTPN2-LysMCre mice.
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Figure 2. IL-10/ Mice Lacking PTPN2 in Myeloid Cells Develop More Severe Colitis
(A) IL-10/mice lacking PTPN2 in myeloid cells (IL-10xPTPN2-LysMCre) and their IL-10/ littermates were monitored for 200 days for prolapse incidence. At
50 and 150 days, mice that did not develop prolapses were analyzed for colitis severity parameters.
(legend continued on next page)
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pro-inflammatory cytokines IL-1b, IL-6, IFN-g, IL-18, MIP-2,
and IL-17 upon induction of colitis and after AOM/DSS
tumor induction (Figure S4). On the other hand, DSS-mediated
induction of IL-10 was reduced, while levels of TGF-b1, TNF,
IL-13, IL-22, and IL-4 were not altered in a consistent pattern
(Figure S4).
Increased levels of the T helper (Th) 1 and Th17 hallmark
cytokines IFN-g and IL-17 prompted us to further address
whether loss of PTPN2 in macrophages affects Th1 and Th17
cell abundance, but there was no difference in CD4+ cells or
in proportions of IFN-g+, IL-17+, or FoxP3+ CD4+ T cells (Fig-
ure S5). Hence we conclude that loss of PTPN2 in macro-
phages does not lead to an overt change in Th cell proportions
in the intestine.
(B–F) Shown are representative pictures from colonoscopy and respective statistical analysis (B), myeloperoxidase (MPO) activity (C), spleen weight (D), colon
length (E), and representative pictures and scoring of epithelial damage and inflammatory infiltration in the terminal colon (F).
Depicted are results from seven or eight mice per group. Asterisks denote significant differences (*p < 0.05 and **p < 0.01; Mann-Whitney U test with Bonferroni
correction). Scale bars represent 100 mm. Error bars represent means ± SD.
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Figure 3. PTPN2-LysMCre Mice Are Pro-
tected from Colitis-Associated Tumor In-
duction
(A) Chronic colitis was induced in WT and PTPN2-
LysMCremice, andsections fromthe terminal colon
were stained for the proliferation marker Ki67.
(B–F) Colitis-associated tumors were induced
in WT and PTPN2-LysMCre mice (B–D) or mice
lacking PTPN2 in intestinal epithelial cells (PTPN2-
VillinCre mice; E and F). Depicted are represen-
tative pictures of colonoscopy and histology of
the terminal colon (B and E), observed tumor
number in dissected colon (C and F), and (D)
average tumor size in each mouse.
Data are representative of one of two independent
experiments with three to five mice per group.
Asterisks denote statistical significance (*p < 0.05;
Mann-Whitney U test with Bonferroni correction).
Scale bars represent 100 mm. Error bars represent
means ± SD. See Figures S4 and S5 for cytokine
levels and T cells in PTPN2-LysMCre mice in the
DSS and DSS/AOM models.
Increased Inflammasome
Activation in Macrophages Lacking
PTPN2
Levels of mature IL-1b, IL-18, and cas-
pase-1, key mediators of inflammasome
activation, were increased in PTPN2-
LysMCre mice during colitis and AOM/
DSS treatment (Figures 4A and S6). Of
note, in isolated IECs from PTPN2-VilCre
mice, we also found increased levels of
mature IL-1b, IL-18, and caspase-1, while
in whole colon pieces we only observed a
trend toward enhanced inflammasome
activity. Therefore, we next investigated if
the loss of PTPN2 in myeloid cells directly
affected inflammasomeactivity orwhether
the altered levels of inflammasome markers were secondary to
elevated inflammation in these mice. PTPN2-deficient BMDMs,
isolated from PTPN2-LysMCre mice, secreted increased levels
of IL-1b in response to NLRP3 inflammasome activators (i.e.,
muramyl dipeptide [MDP], MSU, ATP, nigericin) and to the AIM2
activator double-stranded DNA (dsDNA), but IL-1b production
in response to NLRC4 activation with flagellin was not affected
(Figure 4B). Consistent with our findings in mice and cell culture
experiments, levels of mature IL-1b and IL-18 were enhanced in
the serumof patients carrying an IBD-associated loss-of-function
variant in PTPN2, while levels of TNF, IL-8, and IL-10 were not
altered (Figure 4C). Of note, mRNA expression of IL1B and IL18
was also slightly increased in biopsies from inflamed regions of
the intestine in those patients (Figure 4D).
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In contrast to NLRC4, NLRP3 and AIM2 require the adaptor
molecule ASC for inflammasome assembly, although more
recent findings indicate that ASC might also be involved in effi-
cient NLRC4-mediated caspase-1 activation. ASC is tyrosine
phosphorylated upon inflammasome activation, which is crucial
for the formation of ASC specks, cytosolic structures that
mediate IL-1b cleavage upon inflammasome induction (Hara
et al., 2013). Because PTPN2 is a tyrosine phosphatase, we
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Figure 4. Loss of PTPN2 Promotes ASC-Dependent Inflammasome Activation
(A) Colon pieces fromWT andPTPN2-LysMCremicewith acute DSS colitis were analyzed bywestern blot for NLRP3, IL-1b, caspase-1, and IL-18 expression and
maturation.
(B) BMDMs fromWT and PTPN2-LysMCre mice were treated with indicated inflammasome activators and cell culture supernatants analyzed for IL-1b and IL-18
secretion.
(C) Serum samples from control (non-IBD) patients (n = 15) or CD patients homozygous either for the PTPN2 WT allele (PTPN2 TT, n = 8) or the CD-associated
PTPN2 allele (PTPN2 CC, n = 8) were analyzed for presence of IL-1b and IL-18.
(D) Intestinal biopsies from non-inflamed and inflamed regions were taken from the same patients as in (C) and analyzed for IL1b and IL18 mRNA expression.
(E) BMDMs from WT, PTPN2-LysMCre, and ASC/ mice were left untreated or activated with MSU for 2 hr. ASC was precipitated and analyzed for tyrosine
phosphorylation and co-precipitation of PTPN2.
Results are representative of at least two different experiments, each with three to five mice per group (A) or three or four biological replicates (B and E). Asterisks
denote significant different results (*p < 0.05 and **p < 0.01; Student’s t test with Bonferroni correction). Error bars represent means ± SD. See also Figure S6.
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hypothesized that it might de-phosphorylate ASC and in this way
control inflammasome activity. When precipitating ASC from
BMDMs and THP-1 cells, we indeed found enhanced ASC
phosphorylation in PTPN2-deficient cells (Figure 4E), but there
was no direct interaction between PTPN2 and ASC or other
select inflammasome components, NLRP3 or caspase-1 (Fig-
ures 4E and S6G).
Enhanced Inflammasome Activation Requires JNK
Activity
ASC phosphorylation is mediated via the kinases JNK and Syk
(Hara et al., 2013; Lin et al., 2015), and JNK can serve as a sub-
strate for PTPN2 (Tiganis et al., 1999). Indeed, we found
increased levels of tyrosine phosphorylated JNK and Syk in
MSU-treated PTPN2-deficient BMDMs (Figure 5A). To assess
whether PTPN2-mediated changes in inflammasome activity
are dependent on changes in Syk, JNK, or p38 activity, we
pre-treated BMDMs with the Syk inhibitor R406, the JNK inhibi-
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Figure 5. Inhibition of JNK Prevents Inflam-
masomeActivation in PTPN2-LysMCreMice
(A) BMDMs from WT, PTPN2-LysMCre, and
ASC/ mice were left untreated or activated with
MSU for 2 hr and lysates analyzed for JNK and Syk
phosphorylation and expression of PTPN2, ASC,
and NLRP3. Each lane represents an individual
mouse.
(B and C) BMDMs from WT and PTPN2-LysMCre
(KO) mice were treated with Syk, JNK, or p38 in-
hibitors 1 hr prior to activation with MSU. Analysis
of the cell culture supernatant for IL-1b secretion
(B) and maturation (C) by ELISA and western blot,
respectively.
(D) Precipitation of ASC from the cell lysate and
analysis for tyrosine phosphorylation and co-
precipitated NLRP3 and PTPN2.
Asterisks denote significant differences (*p < 0.05
and **p < 0.01; Student’s t test with Bonferroni
correction). Error bars represent means ± SD. See
also Figure S7.
tor SP600125, or the p38 inhibitor
SB203580 prior to inflammasome activa-
tion. In WT BMDMs, inhibition of Syk or
JNK markedly reduced IL-1b secretion.
PTPN2-deficient BMDMs, however, still
secreted IL-1b upon inhibition of Syk,
while inhibition of JNK abrogated inflam-
masome activation and ASC phosphory-
lation (Figures 5B–5D). Comparable re-
sults were obtained when BMDMs were
treated with Syk- or JNK-specific small
interfering RNA (siRNA) (Figures S7A–
S7C). The p38 inhibitor had no effect on
MSU-stimulated IL-1b secretion in WT
or knockout (KO) BMDMs (Figures 5B
and 5C). Taken together, this indicates
that PTPN2 regulates inflammasome
activation by controlling ASC phosphory-
lation in a JNK-dependent manner. Of
note, similar effects on inflammasome activation were obtained
when we used intestinal epithelial cells (Figures S7D and S7E);
hence we conclude that PTPN2-mediated control of the inflam-
masome is a general mechanism and not confined to macro-
phages or myeloid cells.
Inhibition of IL-1b Protects against Aggravated Colitis in
PTPN2-LysMCre Mice but Increases Tumor Burden
Having shown that PTPN2 controls inflammasome assembly,
we next assessed whether changes in inflammasome activa-
tion are involved in promoting acute inflammation and/or pro-
tection from tumor formation. To interrupt inflammasome acti-
vation in vivo, WT control and PTPN2-LysMCre mice were
administered a vaccine against IL-1b consisting of recombi-
nant murine IL-1b coupled to virus-like particles (VLPs) of the
bacteriophage Qb, as previously described (Spohn et al.,
2008). In response to acute and chronic DSS colitis, PTPN2-
LysMCre mice pre-treated with control VLPs exhibited more
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severe colitis compared with respective WT controls. However,
IL-1b-VLP pre-treated PTPN2-LysMCre mice showed only
mild colitis, comparable with WT animals, indicating that in-
flammasome inhibition protected against the exaggerated in-
flammatory response to DSS in PTPN2-LysMCre mice (Figures
6A–6C [acute colitis], Figures 6D–6F [chronic colitis], and
Figure S8).
In the AOM/DSS tumor model, inhibition of IL-1b by IL-1b-VLP
pre-treatment in PTPN2-LysMCre mice enhanced tumor burden
compared with control VLP-treated PTPN2-LysMCre mice,
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Figure 6. Inhibition of IL-1b Rescues PTPN2-LysMCre Mice from Increased Colitis
WT and PTPN2-LysMCre (KO) mice were immunized with IL-1b-coupled Qb virus-like particles (IL-1b VLP) or with control Qb virus-like particles 5, 3, and 1 week
prior to start of colitis/tumor induction.
(A–C) Weight development (A), representative pictures of H&E-stained pieces of the terminal colon (B), and results of histological scoring of intestinal pathology
(C) from mice with acute DSS colitis.
(D–F) Representative pictures from colonoscopy (D), statistical analysis of histopathology (E), and fibrin score from mice with chronic DSS colitis (F).
(G–I) Representative pictures of colonoscopy (G), observed tumor number in dissected colon (H), and average tumor size (I) in eachmouse frommice subjected to
AOM/DSS treatment.
Results are representative of one of two independent experiments with three to fivemice per group. Asterisks denote statistical significance (*p < 0.05, **p < 0.01,
and *** = p < 0.001; Mann-Whitney U test with Bonferroni correction). Scale bars represent 100 mm. Error bars represent means ±SD. See also Figures S8 and S9.
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reaching a similar number of tumors as observed in WT animals
(Figures 6G and 6H). However, tumors in IL-1b-VLP-treated
PTPN2-LysMCre mice were smaller than those observed in WT
mice andWTmice treated with IL-1b-VLPs (Figure 6I). Similar ef-
fects were observed when we crossed PTPN2-LysMCre mice
with ASC-deficient mice as an alternative approach to interrupt-
ing inflammasome activation (not shown). Thus, inflammasome
inhibition increased tumor burden in AOM/DSS challenged
PTPN2-LysMCre mice. Of note, inhibition of IL-1b normalized
serum cytokine levels of IL-1b, IL-1a, and IL-18 and decreased
mRNA levels of Il1a, Il1b, and Il18 in PTPN2-LysMCre mice
(Figures S9A and S9B), indicating that increased levels of IL-1b
mediate the exaggerated expression of those cytokines.
Enhanced Serum Levels but Reduced
Membrane-Associated IL-1a in PTPN2-LysMCre Mice
In addition to enhanced IL-1b, we also observed increased
serum levels of the structurally related cytokine IL-1a in
PTPN2-LysMCre mice during acute DSS-induced colitis (Fig-
ure 7A). Because IL-1a also exists in a membrane-associated
form, we next addressed whether in PTPN2-LysMCre mice
membrane-associated IL-1a is also affected. Of interest, mem-
brane associated IL-1a was reduced in macrophages and IECs
isolated from PTPN2-LysMCre mice (Figure 7B), while mRNA
levels of calpain, which mediates shedding of membrane-asso-
ciated IL-1a (Carruth et al., 1991), were unchanged (Figure 7C).
Inhibition of IL-1a, using vaccination with IL-1a-VLPs, did
not affect colitis severity (Figures 7D and 7E). However, IL-
1a-VLPs did reduce tumor burden and size in WT but had no ef-
fect on tumorigenesis in PTPN2-LysMCre mice (Figures 7G–7I).
Taken together, our data show that inhibition of IL-1b, but not
IL-1a, can protect PTPN2-LysMCre mice from enhanced colitis
but at the same time re-establishes susceptibility to colitis-
associated tumor induction.
DISCUSSION
In this study, we demonstrate that PTPN2 regulates inflamma-
some activity by restricting phosphorylation of the key inflam-
masome assembly protein ASC. The physiologic importance
of this regulatory mechanism for intestinal health is highlighted
by the fact that lack of PTPN2 in macrophages results in more
severe colitis, which can be prevented by inhibition of IL1-b.
However, inhibition of IL-1b also increased susceptibility to
tumor induction in PTPN2-LysMCre mice. This indicates the
context-dependent nature of inflammasome activity as well as
a clear pathophysiological relevance of PTPN2 loss in myeloid
cells.
Myeloid cell numbers in the intestine were not altered in
PTPN2-LysMCre mice, and there was no effect on the develop-
ment of BMDMs. This is of interest, because PTPN2 has been
implicated to play a role in hematopoiesis (You-Ten et al.,
1997), and it has been described that bone marrow cells from
Ptpn2/ mice are more sensitive to stimulation with granulo-
cyte-macrophage colony-stimulating factor (GM-CSF) and give
rise to more macrophages (Simoncic et al., 2006). However,
another report demonstrated that changes in hematopoiesis
might be due to alterations in bone marrow stromal cell function
and does not necessarily reflect an immune cell-intrinsic effect
on hematopoiesis (Bourdeau et al., 2007). Even though loss of
PTPN2 did not affect monocyte or macrophage numbers in the
intestine, it did have important consequences for intestinal
health by promoting colitis and affecting inflammasome activa-
tion. The role of inflammasomes in intestinal health is controver-
sial, indicating pro- versus anti-inflammatory effects (Bauer
et al., 2010, 2012; Bersudsky et al., 2014; Hirota et al., 2011;
Ruiz et al., 2017; Zaki et al., 2010). To a certain extent, these
contradictions can be explained by differences in the intestinal
microbiota or the use of littermate versus non-littermate controls
(Bauer et al., 2012). To limit the confounding factor of microbiota,
we used littermates for our experiments and caged WT and
PTPN2-LysMCre together until the start of the experiment to
minimize microbiota-associated differences in all experimental
groups.
Besides its influence on anti-microbial properties, lack of
inflammasome activity can impair effective host defense
against invading pathogens during colitis, ultimately resulting
in enhanced disease severity. On the other hand, over-activa-
tion of inflammasomes, and subsequently excess secretion of
mature IL-1b, can mediate tissue damage and promote intesti-
nal inflammation. Our results fit well with this dual-role paradigm
for the inflammasome: inhibition of IL-1b in WT animals, reflect-
ing models with impaired inflammasome activation, results in
slightly enhanced severity of DSS-induced colitis. On the other
hand, PTPN2-LysMCre mice exhibit increased, and therefore
pathogenic, levels of IL-1b. In this highly inflammatory context,
inhibition of (excessive) IL-1b had clear beneficial effects with
respect to reducing inflammation. It is striking that PTPN2-
LysMCre mice, despite enhanced inflammation, exhibit signifi-
cantly reduced tumor burden in the AOM/DSS model of inflam-
mation-driven tumorigenesis. Of interest, we also observed
reduced tumor burden in mice lacking PTPN2 in IECs, indicating
that this effect is not restricted to loss of PTPN2 in myeloid
cells. Taken together, our findings offer additional insights into
a recent publication indicating that PTPN2 promotes evasion
from immune cell-mediated cancer therapy (Manguso et al.,
2017).
Recently, we described that PTPN22, a phosphatase closely
related to PTPN2, promotes NLRP3 inflammasome activity via
de-phosphorylation of NLRP3 (Spalinger et al., 2016). It might
seem surprising that two very similar molecules regulate the
inflammasome in an opposite manner. However, PTPN22 inter-
acts directly with NLRP3, while PTPN2 acts on pathways up-
stream of inflammasome activation (i.e., via regulation of the
kinases responsible for ASC phosphorylation). Our findings
regarding JNK/Syk activity upstream of ASC are in agreement
with the previous work of Hara et al. (2013) and Lin et al.
(2015). Although these publications described the mechanism
of how ASC is phosphorylated, our results demonstrate how
activation of one of the two kinases responsible for ASC phos-
phorylation, namely JNK, is restricted by PTPN2 to prevent
excessive inflammasome induction.
There are reports showing important anti-tumor roles of IL-1b,
as IL-1b activation drives the development of anti-tumor T cells
(Ghiringhelli et al., 2009), and inflammasomes negatively regu-
late tumorigenesis in colitis-associated cancer models (Allen
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et al., 2010; Zaki et al., 2011). Conversely, evidence of IL-1b as
a driver in tumor development is abundant: IL-1b promotes
epithelial-to-mesenchymal transition (Li et al., 2012), a process
involved in tumor development and metastasis (Nieto et al.,
2016); IL-1b, alone or in concert with IL-6, drives tumor angio-
genesis (Voronov et al., 2003); and several studies have shown
a tumor-promoting role for IL-1b/inflammasomes in the context
of colitis-associated tumors (Allen et al., 2010; Bauer et al.,
2012). Our results demonstrate that IL-1b is involved in the pro-
tection against CRC development observed in PTPN2-LysMCre
mice, as inhibition of IL-1b increased susceptibility to tumor
development. However, it is also clear that there must be other
factors involved: upon IL-1b inhibition, tumor numbers in
PTPN2-LysMCre mice were comparable with those in WT ani-
mals, but tumor size was still drastically reduced. Reduced tu-
mor size might result from decreased proliferation, but because
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Figure 7. Inhibition of IL-1a Protects WT Mice from Tumor Induction
(A) Serum from WT and PTPN2-LysMCre mice with chronic DSS colitis was analyzed for IL-1a levels. Dashed line, detection limit of the ELISA.
(B and C) Peritoneal macrophages and intestinal epithelial cells (IECs) from WT and PTPN2-LysMCre mice were analyzed for IL1a surface expression (B) and
calpain mRNA levels (C).
(D–F) WT and PTPN2-LysMCre mice were immunized with IL-1a-coupled Qb virus-like particles (IL-1a VLP) or with control Qb virus-like particles 5, 3, and 1 week
prior to start of colitis and/or tumor induction. (D) Weight development of mice in acute colitis, (E) representative pictures of H&E-stained slides, and
(F) quantification of histology score of terminal colon pieces from WT and PTPN2-LysMCre mice subjected to chronic colitis.
(G–I) Representative pictures of colonoscopy (G), observed tumor number in dissected colon (H), and average tumor size (I) in eachmouse in the AOM/DSS tumor
model.
Results are representative of one of two independent experiments with three to five mice per group. Asterisks denote statistical significance (*p < 0.05; Mann-
Whitney U test with Bonferroni correction). Scale bars represent 100 mm. Error bars represent means ± SD.
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we observed enhanced proliferation in the epithelium of PTPN2-
LysMCre mice, it is questionable as to whether reduced prolifer-
ation is the mechanism resulting in reduced tumor size. More-
over, apoptosis levels were similar in WT and PTPN2-LysMCre
mice, suggesting that elevated apoptosis is not responsible for
decreased tumor size in PTPN2-LysMCre mice. In summary, it
is still unclear how loss of PTPN2 in macrophages protects
against colitis-associated epithelial tumors, and it will be impor-
tant to evaluate this in more detail in future studies.
The IL-1 family of cytokines consists of several members,
including IL-1a. Although IL-1a and IL-1b share little sequence
homology, they are structurally related and both activate the
same receptor, that is, the IL-1 receptor type I (IL-1R1) (March
et al., 1985). Similar to IL-1b, IL-1a is expressed as a pro-form
upon Toll-like receptor (TLR) activation. IL-1b, however, needs
to be cleaved by the inflammasome/caspase-1 to be secreted
in its active form. In contrast, IL-1a is already active in its pro-
form, which can be released by cell death. Also, TLR stimulation
alone is sufficient to induce cell surface expression of IL-1a,
which is biologically active and can be shed by calpains to yield
soluble IL-1a (Kobayashi et al., 1990). Additionally, activation of
the inflammasome leads to IL-1a release (Fettelschoss et al.,
2011). There are reports demonstrating that IL-1a promotes in-
testinal inflammation in cell culture studies (Scarpa et al., 2015)
and in models of acute colitis (Bersudsky et al., 2014). However,
in our hands, inhibition of IL-1a had no overt effect on colitis
severity. Interestingly, however, inhibition of IL-1a resulted in a
drastically reduced tumor burden in WT animals. These mouse
data are in line with the observation that cancer progression
and metastasis correlate with IL-1a expression (reviewed by
Dinarello, 2014), and treatment with monoclonal anti-IL-1a
antibody improves the prognosis of cancer patients (Hong
et al., 2014). Although IL-1a was very effective in reducing
tumorigenesis in WT mice, the already small tumor numbers
in PTPN2-LysMCre mice could not be decreased further. It
is possible that the decreased levels of membrane-bound
IL-1a might contribute to the reduced tumor load observed
in PTPN2-LysMCre mice, further studies are required to make
this determination.
In addition to altered inflammasome-associated cytokine
levels (IL-1b, IL-18, and IL-1a), the Th1- and Th17-associated
cytokines IL-17, IL-6, IL-23, and IFN-g were enhanced in
PTPN2-LysMCre mice, whereas expression of Th2-associated
cytokines IL-4 and IL-13 was decreased. Nevertheless, there
were no changes in the proportion of Th cell subsets isolated
from the colon or mesenteric lymph nodes. This does not neces-
sarily mean that in certain regions or in the tissue directly sur-
rounding tumors the function and proportions of T cell subsets
remain unaltered, but in their overall abundance, T cells seem
not to be affected upon loss of PTPN2 in macrophages.
In summary, we describe an essential role for myeloid cell-
specific PTPN2 in maintaining intestinal homeostasis in the
face of inflammatory challenge. Our results clearly demonstrate
the pathophysiologic relevance of PTPN2 dysfunction and
subsequently altered inflammasome activation in vivo. We
have previously shown that loss or dysfunction of PTPN2 in
T cells is also involved in the pathogenesis of colitis, while
loss of PTPN2 in IECs had little effect on intestinal inflammation.
Dysfunction of PTPN2 in T cells drives the secretion of IFNg and
IL-17, which promote IL-18 and IL-1b secretion, respectively.
Given that in the clinical setting, loss-of-function variants affect
all cell types; dysfunctional PTPN2 in T cells might potentiate
the effect of dysfunctional PTPN2 in macrophages and in
other cell types (Figure S9C). This is underscored by the fact
that none of the reported mouse strains with a tissue-specific
PTPN2 deletion shows the severe inflammatory phenotype
observed in constitutive PTPN2 KO mice. Because of its impor-
tant anti-inflammatory role, PTPN2 might provide an interesting
target for future treatment options in IBD or other inflammatory
disorders. However, our data also point to the need to recog-
nize the importance of context-dependent targeting of PTPN2
signaling given the differential roles observed for myeloid
expressed PTPN2 in inflammation versus inflammation-driven
tumorigenesis.
EXPERIMENTAL PROCEDURES
Mice, Colitis, and Colitis-Associated Tumor Models
All animal experiments were conducted according to Swiss animal welfare
legislation, and the local veterinary office (Veterina¨ramt des Kantons Z€urich)
approved all procedures. All mice used for the studies were homozygous for
the floxed Ptpn2 gene and either heterozygous for the LysMCre construct
(PTPN2-LysMCre) or not expressing LysMCre (WT). Adult (10–12 weeks
old) female littermates housed in a specific pathogen-free (SPF) facility
were used for all studies. Colitis was induced by DSS administration (Becker
et al., 2006; Obermeier et al., 1999), as detailed in Supplemental Experi-
mental Procedures, and by backcrossing the mice onto the IL-10/ back-
ground. For induction of CRC, azoxymethane (AOM; 10 mg/kg body weight;
Sigma-Aldrich) was injected on day 1 and day 8 of each DSS cycle during
chronic DSS colitis induction. Colonoscopy was performed as described
and scored using the murine endoscopic index of colitis severity (MEICS)
scoring system (Becker et al., 2006). Histological scoring for inflammatory
infiltration and epithelial cell damage was performed on H&E-stained section
of the most distal 1 cm of the colon (Becker et al., 2006; Obermeier et al.,
1999).
Immunization Using IL-1b and IL-1a Qb VLPs
Fifty micrograms of IL-1a-Qb, IL-1b-Qb, or Qb-VLP was prepared and diluted
in PBS as previously described (Spohn et al., 2008) and injected subcutane-
ously 5, 3, and 1 week prior to the start of colitis induction. For chronic colitis
and colitis-associated tumor models, a boost immunization was performed
during the recovery phase of the second DSS cycle. Levels of anti-IL-1a and
anti-IL-1b antibodies in the serum were analyzed as previously described
(Spohn et al., 2008) to confirm immunization effectiveness.
H&E, Immunohistochemistry, and Immunofluorescent Staining
Standard protocols were used for H&E, immunohistochemistry, and immuno-
fluorescent staining. Sections of the most distal part of the colon were used
unless otherwise stated. Details on the methods used are given in Supple-
mental Experimental Procedures.
Western Blot Analysis, Immunoprecipitation, ELISA, Flow
Cytometry, and RNA Isolation/RT-PCR
Western blot analysis, immunoprecipitation, flow cytometry, and RNA isolation/
RT-PCRwereperformedaccording tostandardprotocols.ELISAswereobtained
from commercial suppliers and performed according to the manufacturer’s
instructions. Details can be found in Supplemental Experimental Procedures.
Cell Isolation and Cell Culture Experiments
For sorting of immune cells from the spleen, single-cell suspensions were
stained with an appropriate antibody mix and B220+, F4/80+, and CD3+ cells
sorted using a BD Aria III cell sorter. BMDCs were derived from the bone
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marrow and peritoneal macrophages were isolated as previously described
(Spalinger et al., 2016). Further details are given in Supplemental Experimental
Procedures. THP-1 andHT-29 cells were obtained fromDSMZ and cultured as
previously described (Spalinger et al., 2016).
For inflammasome activation, THP-1 cells were differentiated into macro-
phages by treatment with 50 nM PMA (phorbol 12-myristate 13-acetate;
Sigma-Aldrich) for 3 hr. All cells were primed for 12 hr with ultra-pure lipopoly-
saccharide (upLPS; Invivogen) prior to inflammasome activation, unless
otherwise stated. Mono-sodium urate (MSU), ATP, flagellin, and MDP were
obtained from Invivogen. MDP was transfected into the cells using FuGene
transfection reagent (Promega). Flagellin and dsDNA were transfected using
DOTAP transfection reagent (Roche).
Inhibitors and siRNA Treatment
For experiments with kinase inhibition, cells were incubated with Syk inhibitor
R406 (1 mM; Sigma-Aldrich), JNK inhibitor SP600125 (40 mM; Sigma-Aldrich),
or p38 inhibitor SB203580 (10 mM; Sigma-Aldrich) for 1 hr prior to treatment
with MSU (100 ng/mL; Invivogen) (Hara et al., 2013). Transfection was carried
out as detailed in Supplemental Experimental Procedures. After the transfec-
tion, cells were cultured for 24 hr in RPMI supplemented with 10% fetal calf
serum (FCS) prior to activation, as described above.
Patient Serum and Biopsies
Serum and intestinal biopsies were obtained from previously genotyped
(Scharl et al., 2012) CD patients (WT [TT]: n = 15, age range 27–66 years,
mean age 47.4 ± 13.5 years; variant [CC]: n = 8, age range 28–69 years,
mean age 43.8 ± 18.3 years) from the Swiss IBD cohort and from healthy
controls (n = 15, age range 37–61 years, mean age 49.1 ± 9.5 years). Written
informed consent was obtained before sample collection and the local Ethics
Committee of the Canton Z€urich approved the studies (Approval No. EK-1755
and EK-1316). Patients were matched for age, gender, and disease activity.
Statistical Analysis
Data are presented as mean ± SD for one of at least two independent exper-
iments, each with three to six mice or biological replicas as indicated in the
figure legends. Statistical analysis was performed using ANOVA followed by
the Mann-Whitney U or Student’s t test as appropriate. Bonferroni correction
was used to correct for multiple testing as appropriate. p values < 0.05 were
considered to indicate significance.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and nine figures and can be found with this article online at https://doi.org/
10.1016/j.celrep.2018.01.052.
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